When do biologic drug patents expire and when will biosimilars launch?

United States Patent 9,707,153: What claims cover for pneumococcal 13-valent conjugate vaccine vials and glass container IP?

US 9,707,153 is not a vaccine formulation patent in the usual sense. Its independent claim is directed to a pneumococcal 13-valent conjugate vaccine held in a pharmaceutically acceptable excipient inside a specific engineered glass container defined by a narrow glass chemistry window plus optional performance/structure limits on compressive stress, layer depth, delamination factor, and boron exclusion. The enforceable scope is therefore concentrated in (i) the container’s internal glass composition and microstructure and (ii) whether the vial meets quantitative stress and layer metrics. Vaccine makers are likely to be exposed only if they use containers that fall within the claimed glass spec.

Bottom line: the patent estate for US 9,707,153 is strongest when a competitor’s vial glass is engineered to match the claimed chemistry (SiO₂, MgO/CaO, Al₂O₃, Na₂O, and constrained B₂O₃) and is measured to satisfy the claimed compressive stress and layer depth/delamination limits. If competitors use standard borosilicate or other chemically durable pharmaceutical glass without this precise constrained profile, the claims are easier to avoid.

What exactly are the claims of US 9,707,153 and how do they map to measurable container properties?

Claim 1: the core scaffold (chemistry-defined glass + vaccine in the container)

Claim 1 requires a pharmaceutical product comprising pneumococcal 13-valent conjugate vaccine and excipient contained within a glass pharmaceutical container. The container must have a glass composition defined by the following quantitative constraints:

SiO₂: 72 to 78 mol. %
Alkaline earth oxides containing MgO and CaO
- CaO up to ~1.0 mol. %
- and a ratio constraint:
  [ \frac{CaO\ (mol.\%)}{CaO\ (mol.\%) + MgO\ (mol.\%)} \le 0.5 ] This ratio effectively limits Ca’s fraction relative to the Mg+Ca alkaline earth pool.
Al₂O₃: X mol. % where X is 5 to 7 mol. %
Alkali oxide comprising Na₂O:
- Na₂O > 8 mol. % (no upper bound stated in the claim text provided)
B₂O₃ constraint expressed as a ratio: [ \frac{B_2O_3\ (mol.\%)}{(Y\ mol.\% - X\ mol.\%)} \le 0.3 ] where Y mol. % is the total alkali oxide content (as defined by the claim: “Y mol. % alkali oxide, wherein the alkali oxide comprises Na₂O …”).

This claim is a chemistry gate. If a candidate vial glass composition is outside these windows, infringement of claim 1 is unlikely.

Claims 2–5: stress and mechanical surface metrics

Claim 2: compressive stress ≥ 150 MPa
Claim 3: compressive stress ≥ 250 MPa
Claim 4: “depth of layer” > 30 µm
Claim 5: product has “increased stability, product integrity, or efficacy”
- This is a functional statement. In practice, litigating such a clause often turns on whether the container design inherently produces the stated improvements or whether the specification supports the linkage to measurable outcomes.

Claims 6–12: add internal homogeneous layer, delamination control

Claim 6: includes “internal homogeneous layer” plus compressive stress ≥ 150 MPa
Claim 7–8: depth of layer > 10 µm and > 25 µm
Claim 9: “delamination factor < 3”
Claim 10: “increased stability, product integrity, or efficacy”
Claim 11: compressive stress ≥ 150 MPa and depth of layer > 10 µm, plus increased stability/integrity/efficacy
Claim 12: delamination factor < 3 plus increased stability/integrity/efficacy

These are container engineering claims. They target multilayer or strengthened glass behavior (homogeneous internal layer, resistance to delamination).

Claims 13–17: boron-free and higher stress/depth thresholds

Claim 13: container is substantially free of boron, and product has increased stability/integrity/efficacy
Claim 14: boron-free glass plus compressive stress ≥ 150 MPa and depth > 25 µm
Claim 15: boron-free glass plus compressive stress ≥ 300 MPa and depth > 35 µm
Claim 16: “substantially homogeneous inner layer”
Claim 17: homogeneous inner layer plus stress ≥ 150 MPa and depth > 25 µm

The “substantially free of boron” limitation is a key design-around lever. If “substantially free” is construed to exclude typical borosilicate content, many industry standard container glasses are at risk of falling outside this branch. Conversely, if the competitor uses boron-free strengthening glass, the stress/depth metrics become decisive.

Claims 18–19: internal homogeneous layer and functional outcome reiteration

Claim 18: container comprises an “internal homogeneous layer” (without necessarily re-stating the chemical or stress thresholds in the provided text)
Claim 19: claim 9’s product also has increased stability/integrity/efficacy

How can competitors design around US 9,707,153 while still using strengthened glass?

Design-around axis 1: violate the glass chemistry windows (Claim 1)

To avoid claim 1, a defendant can target one of the core chemistry constraints:

move SiO₂ outside 72–78 mol. %
shift Al₂O₃ outside 5–7 mol. %
violate the CaO/MgO ratio (CaO fraction too high)
use a glass where Na₂O is not above 8 mol. % (or the alkali oxide definition differs)
increase B₂O₃ such that the stated ratio exceeds 0.3

Because claim 1 is chemistry-defined, an expert chemical analysis of candidate vial glass composition is likely to become central to infringement/validity arguments.

Design-around axis 2: avoid the stress/depth/delamination numeric thresholds (dependent claims)

Even if a glass might satisfy the chemistry window, many dependent claims hinge on:

compressive stress thresholds (150 MPa, 250 MPa, 300 MPa)
layer depth thresholds (>10, >25, >30, >35 µm)
delamination factor < 3
internal homogeneous layer requirements

Competitors can attempt to achieve partial improvement in product stability with container strength outside the claimed numeric metrics.

Design-around axis 3: boron content strategy (Claim 13 branch)

If a defendant’s container is not “substantially free of boron,” it may avoid the boron-free dependent chain (13–17). But it could still face the main chemistry claim (1), which already constrains B₂O₃ via ratio math.

What patents likely intersect US 9,707,153: glass strengthening, alkali/alkaline earth composition, and measured surface compression?

Because the user provided only the claim text and not the full patent bibliographic details, the analysis below focuses on claim-type overlap risk rather than asserting specific co-pending or cited patent numbers.

High-overlap patent families commonly used in this claim space

US 9,707,153’s claim structure is typical of IP that combines:

Strengthened glass chemistry design (SiO₂/Al₂O₃/Na₂O/CaO/MgO and boron control)
Surface strengthening/ion-exchange behavior that produces compressive stress at the glass surface
Depth-of-layer and delamination metrics to distinguish a particular strengthening process or glass architecture
Pharmaceutical container use coupled to a specific vaccine product

In enforcement, the decisive question usually becomes whether prior art already disclosed:

the same chemistry range and B₂O₃ constraints, and
the same strengthening outcomes (compressive stress and layer depth), and
the same container-type implementation (pharmaceutical vial), and
the same “use” with pneumococcal conjugate vaccine.

If earlier glass patents disclosed chemistry and strengthening performance, the “pneumococcal 13-valent conjugate vaccine” limitation may not provide novelty by itself unless the prior art was limited to different goods or relied on different test methods.

How strong are the infringement and validity positions given the claim’s structure?

Infringement strength: chemistry + measurable stress make proof feasible

For infringement of claim 1 and its dependent stress/layer/delamination branches, a plaintiff typically can:

obtain vial samples from the defendant or licensee supply chain,
perform chemical composition analysis (mol. % for oxides),
measure compressive stress (e.g., stress birefringence or other qualified methods),
measure layer depth and homogeneous interior structure,
measure delamination factor.

This creates a litigation path based on quantitative lab evidence, which can be persuasive.

Validity pressure: broad “product comprising” language plus known glass-strengthening art

The biggest validity risk in this type of claim set is that:

“pharmaceutical product comprising pneumococcal 13-valent conjugate vaccine” may be viewed as an intended use or a non-distinguishing product label, and
the novel element may be construed as the glass engineering constraints alone, which are likely to have overlapping disclosure in older container/strengthened glass patents.

If prior art teaches essentially the same glass chemistry and strengthening performance, novelty and/or non-obviousness can be attacked even if the prior art did not mention pneumococcal 13-valent conjugate vaccine by name.

Functional limitation risk: “increased stability, product integrity, or efficacy”

This element can cut both ways:

Plaintiffs use it to argue performance-driven patentability and to show the claimed structure produces intended benefits.
Defendants use it to argue lack of clear boundaries and potential indefiniteness or non-limiting functionality.

In practice, the functional clause will be anchored to the specification’s test data. Absent strong linkage evidence, it can be weakened in both infringement and validity posture.

What would a generic or biosimilar risk analysis look like for this container patent?

This is not a classic exclusivity bottleneck

The claims are not directed to the antigen, conjugate chemistry, or vaccine manufacturing process. There is no typical ANDA-style “bioequivalence” hook.

Container patents create risk when:

a biosimilar or generic uses the same licensed container supply or replicates the same glass specs.
the claim is asserted against vial purchases regardless of vaccine equivalence.

Risk increases if the same container vendor supplies multiple products

If pneumococcal conjugate products in the US are packaged in similar strengthened glass vials from the same upstream supplier, competitors face higher container infringement risk, especially for the branches that require:

boron-free glass,
internal homogeneous layer,
high compressive stress,
specific depth thresholds,
delamination factor limits.

How should companies evaluate US 9,707,153 in diligence and licensing?

1) Map the claim to the upstream glass spec (not the downstream vaccine)

The most actionable diligence item is:

whether the vial glass supplier can provide oxide composition data in mol. % and confirm it falls within the claim’s SiO₂, Al₂O₃, CaO/MgO ratio, Na₂O and B₂O₃ constraints.

2) Measure or request evidence of stress, layer depth, delamination

A compliance package should include:

compressive stress measurements at relevant positions,
layer depth characterization,
delamination factor tests (for dependent claim coverage),
internal homogeneous layer description.

3) Determine whether the container is “substantially free of boron”

If boron content is present above the meaning of “substantially free,” the boron-free branch (13–17) may not apply, shifting focus back to claim 1’s chemistry ratio constraint for B₂O₃.

4) Licensing posture

Licensing strategies generally target:

a container supplier’s standardized strengthened glass product line
or a specific manufacturing tech-controlled vial architecture that meets compressive stress/depth/delamination limits.

Key claim-to-parameter checklist (use in freedom-to-operate or claim charting)

Claim element	Required parameter	Practical evidence to obtain
Claim 1 glass composition	SiO₂ 72–78 mol.%	Glass composition analysis
Claim 1 alkaline earths	CaO ≤ 1.0 mol.% and CaO/(CaO+MgO) ≤ 0.5	Oxide composition analysis
Claim 1 Al₂O₃	5–7 mol.%	Oxide composition analysis
Claim 1 alkali	Na₂O > 8 mol.% (via Y alkali oxide)	Oxide composition analysis
Claim 1 boron constraint	B₂O₃/(Y − X) ≤ 0.3	Oxide composition analysis + algebra
Claim 2/3 compressive stress	≥150 MPa / ≥250 MPa	Stress measurement report
Claim 4/7/8/11/14/15 layer depth	>10 / >25 / >30 / >35 µm	Depth profiling
Claim 6/16/18 structure	internal homogeneous layer / substantially homogeneous inner layer	Manufacturing architecture evidence
Claim 9 delamination	delamination factor <3	Delamination testing
Claim 13–17 boron-free	substantially free of boron	Boron quantification + standard
Claims 5/10/11/12/19 performance	increased stability/integrity/efficacy	Spec test results or comparative data

Key Takeaways

US 9,707,153 is primarily about engineered pharmaceutical glass containers holding a pneumococcal 13-valent conjugate vaccine. The enforceable hook is the vial glass chemistry plus measurable surface-mechanical properties.
Claim 1 sets a narrow chemistry window (SiO₂, Al₂O₃, Na₂O, CaO/MgO ratio, and a constrained B₂O₃ ratio).
Dependent claims tighten the net via compressive stress, layer depth, delamination factor, and internal homogeneous layer requirements.
Boron strategy matters: the “substantially free of boron” branch creates a distinct infringement axis separate from claim 1’s B₂O₃ ratio math.
For diligence and licensing, the key is upstream glass supplier technical data: oxide composition and stress/layer/de-lamination metrics, not vaccine manufacturing.

FAQs

Which parts of US 9,707,153 are most likely to be litigated?

The chemical oxide windows in claim 1 and the quantitative container performance metrics in dependent claims (compressive stress, layer depth, delamination factor).

Does the patent cover the pneumococcal conjugate vaccine formulation itself?

No. The claims require the vaccine and excipient only insofar as they are contained within a specified glass container meeting chemical and structural/stress limits.

What is the most direct design-around strategy?

Move vial glass composition outside claim 1’s oxide and B₂O₃ ratio constraints, and/or avoid the dependent claim stress/depth/delamination thresholds.

Does “increased stability, product integrity, or efficacy” limit infringement?

It is a claimed functional limitation, so infringement arguments typically turn on whether the container design as claimed is associated with demonstrated improvements in the patent’s disclosure and/or in evidence from accused products.

How does a container vendor change infringement risk for downstream competitors?

If competitors source the same strengthened glass/vial from the same supplier, they face higher risk of meeting the claim’s stress/layer and chemistry requirements. Different vial glass specs can materially reduce exposure.

References (APA)

US Patent 9,707,153, claims provided in user prompt.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Llc	PREVNAR 13	pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)	Injection	125324	February 24, 2010	9,707,153	2034-04-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 9,707,153

Summary for Patent: 9,707,153